rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2011-7-4-492-500rpcardio-874Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACIDК 125-ЛЕТИЮ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫБокаревИ. Н.BokarevI. N.

д.м.н., профессор кафедры госпитальной терапии № 1

ПоповаЛ. В.PopovaL. V.

к.м.н., доцент кафедры госпитальной терапии № 1

mila_foka@mail.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Setchenov First Moscow State Medical UniversityRussian Federation20111901201674492500Copyright © Bokarev I.N., Popova L.V., 20162016Бокарев И.Н., Попова Л.В.Bokarev I.N., Popova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/874

An experience of acetylsalicylic acid (ASA) clinical use since its synthesis in 1887 is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered. The evidence based clinical data on ASA treatment and the problem of antiplatelet therapy resistance are discussed. ASA interaction with other drugs and ASA pleiotropic effects are reviewed

 

Освещается опыт клинического применения ацетилсалициловой кислоты (АСК) с момента ее синтеза в 1887 г. Рассматриваются особенности механизма действия и место АСК среди современных антитромбоцитарных средств. Приводится доказательная база клинического применения АСК, а также обсуждается проблема резистентности к антитромбоци-тарной терапии. Рассматривают особенности взаимодействия различных препаратов с АСК и её плейотропные эффекты.

ацетилсалициловая кислотааспиринантитромбоцитарные средстваacetylsalicylic acidaspirinantiplatelet drugsReferencesRosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146.Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146.Gawaz M., editor. Blood platelets — clinical relevance. Stuttgart: Georg Thieme Verlag; 2010.Gawaz M., editor. Blood platelets — clinical relevance. Stuttgart: Georg Thieme Verlag; 2010.Gershlick A.H. Antiplatelet therapy. Hosp Med 2000;61: р15-23Gershlick A.H. Antiplatelet therapy. Hosp Med 2000;61: р15-23Schror K. Antiplatelets drugs. A comparative review. Drugs 1995; 50: р 7-28.Schror K. Antiplatelets drugs. A comparative review. Drugs 1995; 50: р 7-28.PatronoC., Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl. 1): 258-61.PatronoC., Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl. 1): 258-61.Patrono C., Baigent C., Hirsh J., Roth G. Аntiplatelet Drugs. Chest 2008;133 (6 suppl):199S-233S.Patrono C., Baigent C., Hirsh J., Roth G. Аntiplatelet Drugs. Chest 2008;133 (6 suppl):199S-233S.Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treat¬ment andprophylaxis. Semin Thromb Hemost 1997;23: 349-356.Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treat¬ment andprophylaxis. Semin Thromb Hemost 1997;23: 349-356.Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone—mechanisms of action and therapeutic implications. Eur Heart J 1993; 14 Suppl: 34-41.Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone—mechanisms of action and therapeutic implications. Eur Heart J 1993; 14 Suppl: 34-41.Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206–1211.Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206–1211.Antithrombotic Trials Collaboration. Prevantion of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 2002; 324: 71-86.Antithrombotic Trials Collaboration. Prevantion of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 2002; 324: 71-86.Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta–analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849–1860.Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta–analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849–1860.U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force. Recommendation statement. Ann Intern Med 2009; 150 (6): 396–404.U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force. Recommendation statement. Ann Intern Med 2009; 150 (6): 396–404.AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-91.AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-91.Buse J.B., Ginsberg H.N., Bakris G.L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115(1):114-26.Buse J.B., Ginsberg H.N., Bakris G.L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115(1):114-26.Algra A., Greving J.P. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009; 373: 1821–22.Algra A., Greving J.P. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009; 373: 1821–22.Lindemann S., Tolley N., Dixon D. et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485-490Lindemann S., Tolley N., Dixon D. et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485-490Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.Yeomans N.D., Lanas A.I., Talley N.J. et al. Prevalence and incidence of gas-troduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.Yeomans N.D., Lanas A.I., Talley N.J. et al. Prevalence and incidence of gas-troduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gas-troenterol 2008;103:323-332.Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gas-troenterol 2008;103:323-332.Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-17.Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-17.Muller I., Seyfarth M., Rudiger S. et al. Effect of a high loading dose of Clopidogrel on platelet function in patients undergoing coronary stent place¬ment. Heart 2001; 85: 92-93.Muller I., Seyfarth M., Rudiger S. et al. Effect of a high loading dose of Clopidogrel on platelet function in patients undergoing coronary stent place¬ment. Heart 2001; 85: 92-93.Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001:88:230-235.Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001:88:230-235.Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implica¬tions for the use of ASA clinically. Can J Cardiol 1995:11: 221-227Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implica¬tions for the use of ASA clinically. Can J Cardiol 1995:11: 221-227Cotter G., Shemesh E., Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300.Cotter G., Shemesh E., Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300.Schwartz K.A., Schwartz D.E., Ghosheh K. et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975.Schwartz K.A., Schwartz D.E., Ghosheh K. et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975.Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects ofaspirin. N Engl J Med 2001;345: 1809-1817.Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects ofaspirin. N Engl J Med 2001;345: 1809-1817.Borna C., Lazarowski E., van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myo-cardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.Borna C., Lazarowski E., van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myo-cardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.Fateh-Moghadam S., Plockinger U., Cabeza N. et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103.Fateh-Moghadam S., Plockinger U., Cabeza N. et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103.Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thrombos Haemostas 2005;3:2340–2345.Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thrombos Haemostas 2005;3:2340–2345.Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:8:2153-2158.Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:8:2153-2158.Santoso S., Kunicki T.J., Kroll H. et al. Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-2253.Santoso S., Kunicki T.J., Kroll H. et al. Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-2253.Gonzalez-Conejero R., Lozano M.L., Rivera J. et al. Polymorphisms of platelet membrane glycopro-tein Ib associated with arterial thrombotic disease. Blood 1998; 92(8): 2771-2776.Gonzalez-Conejero R., Lozano M.L., Rivera J. et al. Polymorphisms of platelet membrane glycopro-tein Ib associated with arterial thrombotic disease. Blood 1998; 92(8): 2771-2776.Carlsson L.E., Greinacher A., Spitzer C. et al. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fib-rinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28(7): 1392-1395.Carlsson L.E., Greinacher A., Spitzer C. et al. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fib-rinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28(7): 1392-1395.Ardissino D., Mannucci P.M., Merlini P.A. et al. Pro-thrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94(1): 46-51.Ardissino D., Mannucci P.M., Merlini P.A. et al. Pro-thrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94(1): 46-51.Ollikainen E., Mikkelsson J., Perola M. et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-99.Ollikainen E., Mikkelsson J., Perola M. et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-99.Bray P.F., Howard T.D., Vittinghoff E. et al. Effect of genetic variations in platelet glycoproteins Ibal-pha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007; 109(5): 1862-1869.Bray P.F., Howard T.D., Vittinghoff E. et al. Effect of genetic variations in platelet glycoproteins Ibal-pha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007; 109(5): 1862-1869.Yu Z.Q., Dong N.Z., Gao W.Q. et al. Study on T13254C polymorphism of the platelet membrane glycoprotein VI in Chinese Han population. Zhonghua Xue Ye Xue Za Zhi 2005; 26(3): 140-143.Yu Z.Q., Dong N.Z., Gao W.Q. et al. Study on T13254C polymorphism of the platelet membrane glycoprotein VI in Chinese Han population. Zhonghua Xue Ye Xue Za Zhi 2005; 26(3): 140-143.Fontana P., Gaussem P., Aiach M. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-2973.Fontana P., Gaussem P., Aiach M. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-2973.Hetherington S.L., Singh R.K., Lodwick D. et al. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vase Biol 2005; 251(1): 252-257.Hetherington S.L., Singh R.K., Lodwick D. et al. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vase Biol 2005; 251(1): 252-257.Li Q., Chen B.L., Ozdemir V. et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8(6): 577-586.Li Q., Chen B.L., Ozdemir V. et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8(6): 577-586.Evans W.E., McLeod H.L. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.Evans W.E., McLeod H.L. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxyge-nase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxyge-nase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.Lepantalo A., Mikkelsson J., Resendiz J.C. et al. Polymorphisms of COX-1 and GPV1 associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.Lepantalo A., Mikkelsson J., Resendiz J.C. et al. Polymorphisms of COX-1 and GPV1 associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.Gonzalez-Conejero R., Rivera J., Corral J. et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.Gonzalez-Conejero R., Rivera J., Corral J. et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.Matsubara Y., Murata M., Maruyama T. et al. Association between diabetic retinopathy and genetic variations in alpha2betal integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.Matsubara Y., Murata M., Maruyama T. et al. Association between diabetic retinopathy and genetic variations in alpha2betal integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.Leor J., Reicher-Reiss H., Goldbourt U. et al. Aspirin and mortality in patients treated with angioten-sin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920-1925.Leor J., Reicher-Reiss H., Goldbourt U. et al. Aspirin and mortality in patients treated with angioten-sin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920-1925.Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.Cleland J.G., Bulpitt C.J., Falk R.H. et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74:215-219.Cleland J.G., Bulpitt C.J., Falk R.H. et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74:215-219.Strand V. Are COX-2 Inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with the risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370 (9605): 2138-2151.Strand V. Are COX-2 Inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with the risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370 (9605): 2138-2151.Singh G., Graham D., Wang H. et al. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cycloocygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65: 61.Singh G., Graham D., Wang H. et al. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cycloocygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65: 61.Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.Rothwell P.M., Wilson M., Elwin C.E. et al. Long-term effect of aspirin on col-orectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010;376(9754):1741-50.Rothwell P.M., Wilson M., Elwin C.E. et al. Long-term effect of aspirin on col-orectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010;376(9754):1741-50.Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2010;38 Suppl:S1-S52.Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2010;38 Suppl:S1-S52.

The authors declare that there are no conflicts of interest present.